Laboratory Corp. of America Holdings (NYSE:LH) reached a new 52-week high on Wednesday . The stock traded as high as $138.21 and last traded at $137.94, with a volume of 421,140 shares trading hands. The stock had previously closed at $136.80.

LH has been the subject of several recent research reports. Canaccord Genuity increased their price target on Laboratory Corp. of America Holdings from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, April 26th. KeyCorp reaffirmed a “buy” rating and set a $143.00 price target on shares of Laboratory Corp. of America Holdings in a report on Sunday, May 22nd. Robert W. Baird reaffirmed a “buy” rating on shares of Laboratory Corp. of America Holdings in a report on Monday, May 16th. Zacks Investment Research raised Laboratory Corp. of America Holdings from a “hold” rating to a “buy” rating and set a $143.00 price target for the company in a report on Tuesday, May 17th. Finally, Morgan Stanley reissued a “buy” rating on shares of Laboratory Corp. of America Holdings in a report on Monday, May 2nd. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Laboratory Corp. of America Holdings presently has a consensus rating of “Buy” and an average price target of $135.50.

The company has a market capitalization of $14.12 billion and a PE ratio of 23.92. The company has a 50 day moving average price of $131.27 and a 200-day moving average price of $120.26.

Laboratory Corp. of America Holdings (NYSE:LH) last announced its quarterly earnings results on Monday, April 25th. The company reported $2.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.96 by $0.06. The business had revenue of $2.30 billion for the quarter, compared to analyst estimates of $2.19 billion. The company’s revenue was up 29.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.73 EPS. On average, equities analysts expect that Laboratory Corp. of America Holdings will post $8.79 earnings per share for the current year.

In other Laboratory Corp. of America Holdings news, insider Edward T. Dodson sold 9,392 shares of the business’s stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $126.42, for a total transaction of $1,187,336.64. Following the completion of the transaction, the insider now owns 2,717 shares in the company, valued at approximately $343,483.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David P. King sold 196,400 shares of the business’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $128.00, for a total value of $25,139,200.00. Following the transaction, the chief executive officer now owns 271,210 shares of the company’s stock, valued at approximately $34,714,880. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. TD Asset Management Inc. raised its position in shares of Laboratory Corp. of America Holdings by 2.6% in the fourth quarter. TD Asset Management Inc. now owns 47,184 shares of the company’s stock worth $5,834,000 after buying an additional 1,200 shares during the period. ProShare Advisors LLC raised its stake in shares of Laboratory Corp. of America Holdings by 6.0% in the fourth quarter. ProShare Advisors LLC now owns 17,791 shares of the company’s stock valued at $2,200,000 after buying an additional 1,002 shares during the period. Gabelli Funds LLC raised its stake in shares of Laboratory Corp. of America Holdings by 14.6% in the fourth quarter. Gabelli Funds LLC now owns 78,500 shares of the company’s stock valued at $9,706,000 after buying an additional 10,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Laboratory Corp. of America Holdings by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 8,702,664 shares of the company’s stock valued at $1,075,997,000 after buying an additional 308,110 shares during the period. Finally, GAM Holding AG raised its stake in shares of Laboratory Corp. of America Holdings by 5.5% in the fourth quarter. GAM Holding AG now owns 30,213 shares of the company’s stock valued at $3,736,000 after buying an additional 1,563 shares during the period.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.